Novel markers of normal and neoplastic human plasmacytoid dendritic cells
(2008) In Blood 111(7). p.3778-3792- Abstract
- Plasmacytoid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4(+)CD56(+) hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions... (More)
- Plasmacytoid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4(+)CD56(+) hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions where pDCs are greatly increased (eg, Kikuchi disease). Most of the molecules were retained in the majority of pDC neoplasms, and 3 (BCL11A, CD2AP, and ICSBP/IRF8) were also commonly negative in leukemia cutis (acute myeloid leukemia in the skin), a tumor that may mimic pDC neoplasia. In summary, we have documented a range of molecules (notably those associated with B cells) expressed by pDCs in tissues and peripheral blood (where pDCs were detectable in cytospins at a frequency of < 1% of mononuclear cells) and also defined potential new markers (in particular CD2AP) for the diagnosis of pDC tumors. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1182711
- author
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 111
- issue
- 7
- pages
- 3778 - 3792
- publisher
- American Society of Hematology
- external identifiers
-
- wos:000254569300067
- scopus:43549106155
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2007-10-117531
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000)
- id
- e55014dd-711e-4506-8c28-5a56a42661dd (old id 1182711)
- date added to LUP
- 2016-04-01 12:02:43
- date last changed
- 2022-01-26 22:01:48
@article{e55014dd-711e-4506-8c28-5a56a42661dd, abstract = {{Plasmacytoid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4(+)CD56(+) hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions where pDCs are greatly increased (eg, Kikuchi disease). Most of the molecules were retained in the majority of pDC neoplasms, and 3 (BCL11A, CD2AP, and ICSBP/IRF8) were also commonly negative in leukemia cutis (acute myeloid leukemia in the skin), a tumor that may mimic pDC neoplasia. In summary, we have documented a range of molecules (notably those associated with B cells) expressed by pDCs in tissues and peripheral blood (where pDCs were detectable in cytospins at a frequency of < 1% of mononuclear cells) and also defined potential new markers (in particular CD2AP) for the diagnosis of pDC tumors.}}, author = {{Marafioti, Teresa and Paterson, Jennifer C and Ballabio, Erica and Reichard, Kaaren K and Tedoldi, Sara and Hollowood, Kevin and Dictor, Michael and Hansmann, Martin-Leo and Pileri, Stefano A and Dyer, Martin J and Sozzani, Silvano and Dikic, Ivan and Shaw, Andrey S and Petrella, Tony and Stein, Harald and Isaacson, Peter G and Facchetti, Fabio and Mason, David Y}}, issn = {{1528-0020}}, language = {{eng}}, number = {{7}}, pages = {{3778--3792}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Novel markers of normal and neoplastic human plasmacytoid dendritic cells}}, url = {{http://dx.doi.org/10.1182/blood-2007-10-117531}}, doi = {{10.1182/blood-2007-10-117531}}, volume = {{111}}, year = {{2008}}, }